Each step in the testing program “brings us closer" to "the future of commercial supersonic flight," the project manager of ...
As the Ebola epidemic raging in the Democratic Republic of the Congo shows no signs of abating, researchers around the world ...
Two suspected cases of Ebola in Brazil have been cleared after both patients tested negative for the virus, local health ...
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of ...
A study finds that an mRNA vaccine is highly effective at preventing recurrence of this dangerous skin cancer, when used in ...
After a prior misfire in demonstrating its protease inhibitor ensitrelvir’s potential as a COVID-19 treatment for U.S. patients, Shionogi has secured an FDA green light for the medicine in the ...
Moderna Inc. (NASDAQ:MRNA) stands at a critical juncture as the biotechnology company transitions from its COVID-19 vaccine success toward a diversified pipeline of treatments and vaccines. The ...
The move: Moderna stock popped, before paring losses as investors eye it as a play on the emerging hantavirus threat. Shares opened Monday's session higher, with the stock peaking around 22% from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results